DRDO invites EoI to transfer technology of 2-DG drug for bulk production
The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories.
The Defence Research and Development Organisation (DRDO), which developed 2-Deoxy-D- Glucose (2-DG), a drug used for remedy of COVID-19 sufferers, has known as for Expression of Interest (EoI) to transfer the technology to Indian pharmaceutical industries for production.
The 2-DG was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr. Reddy’s Laboratories.
Clinical trial outcomes have proven that this molecule helps in quicker restoration of hospitalised sufferers and reduces supplemental oxygen dependence.
Questions stay on DRDO’s COVID drug
Higher proportion of sufferers handled with 2-DG confirmed RT-PCR detrimental conversion in COVID-19 sufferers. According to the EoI doc, purposes must be submitted earlier than June 17 by means of electronic mail.
“The EoI submitted by industries will be scrutinised by a Technical Assessment Committee (TAC).
Only up to 15 industries will be given ToT on their capabilities, technical hand holding capability of DRDO and on first-come-first-served basis,” it stated.
The bidders ought to have a Drug license to manufacture Active Pharmaceutical Ingredient (API) from Drug Licensing Authorities and WHO GMP (Good manufacturing Practices) certification amongst others.
Laboratory synthesis course of for 2-DG has been developed utilizing D-Glucose as beginning materials. The synthesis course of consists of conversion of D-Glucose to 2-DG by means of 5 chemical response steps adopted by purification.
The course of has been established at batch scale (100g) and pilot plant scale (500g) and vital patents have been filed by DRDO on this regard, the Defence physique stated.